论文部分内容阅读
狗实验性心律不齐模型试验结果表明,多沙唑嗪(Doxazosin)的抗心律不齐作用可能是阻滞心肌α_1受体的结果。家兔等多种类的动物试验中,本品类似prazosin,能阻滞α_1受体而降低血压,其持久的降压和α_1阻滞活性提示本品的代谢产物也具有同样的药理作用。老年健康志愿受试者试验结果表明,药物分布不存在性别差异。与年轻健康受试者相比,前者分布容积较大,而两者在生物利用度和清除率方面无明显差异,说明年龄对药物分布无明显影响。年轻受试者口服本品2 mg或静注1mg,平均终末半衰期为9小时,口服平均生物利用度为63%,平均清除率为每分钟
The results of the experimental model of experimental arrhythmia in dogs showed that the antiarrhythmic effect of Doxazosin may be the result of blocking the cardiac α_1 receptor. Rabbits and other animal experiments, the product is similar to prazosin, can block the α_1 receptor and lower blood pressure, its long-lasting antihypertensive and α_1 blocking activity prompted the metabolites of this product also has the same pharmacological effects. The results of the trials of healthy volunteers in older age show that there is no gender difference in drug distribution. Compared with young healthy subjects, the former has a larger volume of distribution, while the latter has no significant difference in bioavailability and clearance, indicating that age has no obvious effect on drug distribution. Young subjects oral 2 mg of the goods or intravenous 1mg, the average terminal half-life of 9 hours, the average oral bioavailability was 63%, the average clearance rate per minute